The association of socio-economic status, race, psychosocial factors and outcome in patients with systemic lupus erythematosus

被引:107
作者
Sutcliffe, N
Clarke, AE
Gordon, C
Farewell, V
Isenberg, DA
机构
[1] UCL, Bloomsbury Rheumatol Unit, Dept Med, Ctr Rheumatol, London W1P 9PG, England
[2] McGill Univ, Montreal Gen Hosp, Div Clin Immunol & Allergy, Montreal, PQ H3G 1A4, Canada
[3] McGill Univ, Montreal Gen Hosp, Div Clin Epidemiol, Montreal, PQ H3G 1A4, Canada
[4] Univ Birmingham, Div Immun & Infect, Dept Rheumatol, Birmingham, W Midlands, England
[5] UCL, Dept Stat Sci, London, England
关键词
SLE; socio-economic status; race; psychosocial factors; organ damage; disease activity;
D O I
10.1093/rheumatology/38.11.1130
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To determine the relationship between socio-economic status, race, psychosocial factors and outcome in patients with systemic lupus erythematosus (SLE). Methods. One hundred and ninety-five patients with SLE were studied at two centres in the UK (London and Birmingham). information about sociodemographics, income, employment status, social support and satisfaction with care was obtained. Outcomes were assessed by end-organ damage, disease activity and employment status. Results. Non-Caucasian race, longer disease duration, higher disease activity and lower level of education were associated with more organ damage in SLE. More satisfaction with access to care and interpersonal aspects of care, but less satisfaction with time spent with doctors, were also associated with more damage. Very long disease duration was associated with higher disease activity. Patients with higher disease activity, lower level of education and from the Birmingham centre were more likely not to be working due to their lupus. Conclusion. Race and socio-economic status, as well as clinical and psychosocial factors, determine outcome in SLE.
引用
收藏
页码:1130 / 1137
页数:8
相关论文
共 28 条
  • [1] Alarcón GS, 1998, ARTHRITIS RHEUM-US, V41, P1173, DOI 10.1002/1529-0131(199807)41:7<1173::AID-ART5>3.0.CO
  • [2] 2-A
  • [3] DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS
    BOMBARDIER, C
    GLADMAN, DD
    UROWITZ, MB
    CARON, D
    CHANG, CH
    [J]. ARTHRITIS AND RHEUMATISM, 1992, 35 (06): : 630 - 640
  • [4] Clarke AE, 1999, J RHEUMATOL, V26, P1500
  • [5] A CANADIAN STUDY OF THE TOTAL MEDICAL COSTS FOR PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS AND THE PREDICTORS OF COSTS
    CLARKE, AE
    ESDAILE, JM
    BLOCH, DA
    LACAILLE, D
    DANOFF, DS
    FRIES, JF
    [J]. ARTHRITIS AND RHEUMATISM, 1993, 36 (11): : 1548 - 1559
  • [6] Cohen S., 1985, NATO ASI Series, V24, P73, DOI DOI 10.1007/978-94-009-5115-0_5
  • [7] The development and initial validation of the systemic lupus international collaborating clinics American College of Rheumatology Damage Index for Systemic Lupus Erythematosus
    Gladman, D
    Ginzler, E
    Goldsmith, C
    Fortin, P
    Liang, M
    Urowitz, M
    Bacon, P
    Bombardieri, S
    Hanly, J
    Hay, E
    Isenberg, D
    Jones, J
    Kalunian, K
    Maddison, P
    Nived, O
    Petri, M
    Richter, M
    SanchezGuerrero, J
    Snaith, M
    Sturfelt, G
    Symmons, D
    Zoma, A
    [J]. ARTHRITIS AND RHEUMATISM, 1996, 39 (03): : 363 - 369
  • [8] Gladman Dafna D., 1995, Current Opinion in Rheumatology, V7, P402, DOI 10.1097/00002281-199509000-00007
  • [9] Gladman Dafna D., 1994, Current Opinion in Rheumatology, V6, P487, DOI 10.1097/00002281-199409000-00006
  • [10] The reliability of the systemic Lupus International Collaborating Clinics American College of Rheumatology Damage Index in patients with Systemic Lupus Erythematosus
    Gladman, DD
    Urowitz, MB
    Goldsmith, CH
    Fortin, P
    Ginzler, E
    Gordon, C
    Hanly, JG
    Isenberg, DA
    Kalunian, K
    Nived, O
    Petri, M
    SanchezGuerrero, J
    Snaith, M
    Sturfelt, G
    [J]. ARTHRITIS AND RHEUMATISM, 1997, 40 (05): : 809 - 813